SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending as the community eagerly awaits the February 21st Bysanti PDUFA decision and anticipates the "mega blockbuster" potential of Tradipitant for GLP-1 induced nausea, leading to widespread speculation of a significant valuation re-rating or a major buyout.

Infosys Ltd. is a digital services and consulting company, which engages in the provision of end-to-end business solutions. It operates through the following segments: Financial Services, Retail, Communication; Energy, Utilities, Resources, and Services; Manufacturing, Hi-Tech, Life Sciences, and All Other. The company was founded by Dinesh Krishnan Swamy, Senapathy Gopalakrishnan, Narayana Ramarao Nagavara Murthy, Raghavan N. S., Ashok Arora, Nandan M. Nilekani, and S. D. Shibulal on July 2, 1981 and is headquartered in Bangalore, India.

Infosys Ltd - ADR

Infosys Technologies Limited

Intense community discussions surrounding the disruptive potential of new AI automation tools, exemplified by Anthropic's innovations, are driving Infosys' trend, with many fearing a significant erosion of the traditional Indian IT service model. This prevailing concern overshadows the company's latest positive earnings report, fueling widespread investor frustration over persistent underperformance and a generally bearish outlook.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor (TAO) is trending due to its imminent token halving and recent Binance Japan listing, amplified by Grayscale's ETF filing, fueling community discussion around its scarce tokenomics and potential as the "Bitcoin of AI" for decentralized intelligence. Investors are actively exploring staking opportunities within its innovative subnet ecosystem as a key talking point.

Arista Networks, Inc. engages in the development, marketing, and sale of cloud networking solutions. Its solutions include EOS, a set of network applications, and Gigabit Ethernet switching and routing platforms. Its product categories include Core, Cognitive Adjacencies, and Network Software and Services. The company was founded by Andreas Bechtolsheim, David Cheriton, and Kenneth Duda in November 2004 and is headquartered in Santa Clara, CA.

Arista Networks Inc

Arista Networks is trending following a strong earnings beat and raised full-year outlook, driven by robust demand for its AI networking and cloud solutions. Despite initial market fluctuations, the community largely views any dips as buying opportunities, citing the company's crucial role in AI infrastructure and numerous analyst price target increases.

Accenture is a global professional services company that helps the world’s businesses, governments and other organizations build their digital core, optimize their operations, accelerate revenue growth and enhance citizen services, creating tangible value at speed and scale. The firm combines technology and leadership in cloud, data and AI with industry experience, functional expertise and global delivery capability. Its services include Strategy & Consulting, Technology, Operations, Industry X, and Song. It operates through the following geographical segments: North America, EMEA, and Growth Markets. The company was founded in 1989 and is headquartered in Dublin, Ireland.

Accenture plc - Ordinary Shares - Class A

Accenture is trending following its recent Q3 results, which, despite an EPS beat, revealed softer bookings and a cautious outlook, intensifying community debate on whether AI poses a disruptive threat to consulting services or positions Accenture as an indispensable integration partner. Sentiment is split between those buying the dip on perceived AI growth catalysts and others anticipating further downside amid a challenging discretionary spending environment.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

The Compound (COMP) community is actively discussing its maxed-out token supply and current low valuations, with many anticipating a significant rebound driven by upcoming V4 developments and potential fintech partnerships. This bullish outlook is met with skepticism regarding the token's ability to sustain gains, given its historical underperformance and ongoing governance concerns.

Polygon

Polygon is drawing significant attention for its strategic pivot into regulated payments and Real-World Assets, bolstered by a recent $250 million acquisition to expand its infrastructure. The community is noting its surging stablecoin volume, ongoing network innovations like the AggLayer, and a deflationary token burn, leading many to view POL as a fundamentally strong yet undervalued asset.

Vanguard Group, Inc. - Vanguard S&P 500 ETF

Vanguard S&P 500 ETF

VOO is actively discussed for its significant inflows, highlighting its role as a core S&P 500 investment, while the community debates the broader market's direction amid recent inflation data and concerns over stretched valuations in tech.

Amentum Holdings, Inc. engages in mission-critical, technology-driven services in government and commercial markets. It operates through the Digital Solutions and Global Engineering Solutions segments. The Digital Solutions segment provides advanced digital and data-driven solutions including intelligence analytics, space system development, cybersecurity, and next generation IT. The Global Engineering Solutions segment manages large-scale environmental remediation, nuclear power solutions, platform engineering, sustainment and supply chain management. The company was founded on November 26, 2019 and is headquartered in Chantilly, VA.

Amentum Holdings Inc.

Amentum Holdings is trending as the community views its recent earnings revenue miss as an overreaction, highlighted by reaffirmed guidance and a rapidly expanding multi-billion dollar backlog from key defense, nuclear, and space contracts. Amidst robust new contract wins and an expanding role in critical sectors, the community remains highly bullish, anticipating substantial long-term growth for this "under the radar" defense and energy giant.

clawdbot

CLAWD CRYPTO is trending due to community discussions indicating a breakout and significant upward movement, with many speculating on its limitless potential as a future investing AI, while some express caution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc. - AQST

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc. - AQST INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics

INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of...

HC Wainwright Has Pessimistic Outlook of AQST Q3 Earnings

Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) - HC Wainwright cut their Q3 2026 earnings per share estimates for shares of Aquestive Therapeutics in a research note issued to investors on...

<ul class="summary-bullets"><li>The FDA’s concerns were limited to packaging, labeling, and administration issues, the company said.</li><li>Aquestive has already modified the pouch design, updated instructions for use, and revised labelling.</li><li>The firm is also targeting global expansion plans for Anaphylm after initiating regulatory discussions in Canada, Europe, and the U.K last year.</li></ul>Shares of Aquestive Therapeutics (AQST) surged more than 35% on Monday morning, after receiving a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) seeking approval of Anaphylm, a sublingual film to treat severe Type I allergic reactions.A CRL indicates that while a drug has not been approved in its current form, it allows the sponsor to address the issues raised by the FDA and seek re-approval.<h2 class="st-heading-2">FDA’s Concerns</h2>The FDA’s concerns were limited to packaging, labeling, and administration issues identified in a human factors validation study. The FDA noted that some users had difficulty opening the pouch and correctly placing the film, which could pose safety risks during emergency situations. The agency did not raise questions about the drug’s comparability data or manufacturing processes, the company said.To address the feedback, Aquestive has modified the pouch design, updated instructions for use, and revised labeling. The company plans to conduct a new human factors study alongside a single pharmacokinetics (PK) study requested by the FDA. No additional trials are required.Based on the initial review, Aquestive expects to resubmit the application as early as the third quarter of 2026 and will seek a rapid review.<h2 class="st-heading-2">Europe Update</h2>Aquestive is also targeting global expansion plans for Anaphylm after initiating regulatory discussions in Canada, Europe, and the U.K. in 2025. The European Medicines Agency indicated that no additional clinical trials are required, with submissions in Europe and Canada expected in the second half of 2026. The company also anticipates feedback from the U.K.’s MHRA in the first quarter of 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘bullish’ from ‘neutral’ a session earlier, amid ‘high’ message volumes.&nbsp;<img src="https://news.stocktwits-cdn.com/AQST_jpg_c092cd62f6.webp" alt="AQST.jpg">One user brushed off concerns about the CRL, noting there were no key issues.<stembedurl>https://stocktwits.com/BigGainTom/message/643649716</stembedurl>While the stock has gained nearly 35% over the past year, its year-to-date losses are around 40%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/precious-metals-extend-historic-rout/cZbg8EJR4kf">Gold, Silver Continue To Decline – Analysts Warn Of Crowded Trades As Precious Metals Extend ‘Historic Rout’</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

A candlestick chart can be seen in a trading platform on a smartphone. Top U.S. firms announced record buybacks this year. (Photo by Silas Stein/picture alliance via Getty Images)

Why Did AQST Stock Jump 35% Today?

The company received a Complete Response Letter from the U.S. Food and Drug Administration for its New Drug Application seeking approval of Anaphylm, a sublingual film to treat severe Type I allergic reactions.

Equity

Markets Kick Off Super Bowl Week

U.S. markets Kick off Super Bowl week, as today’s news flow highlights how niche operators are quietly building momentum across gaming, mobility, retail automation, AI infrastructure, biotech, and advanced materials.

Aquestive Therapeutics (NASDAQ:AQST) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen lowered Aquestive Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday...

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive...

INVESTIGATION ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics

INVESTIGATION ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics INVESTIGATION ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of...

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Consensus Rating of "Buy" from Analysts

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) have received a consensus recommendation of "Buy" from the ten analysts that are covering the stock, Marketbeat.com reports. One...

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Aquestive Therapeutics Inc

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

The Nasdaq 100 continues to hinge on mega-cap tech and AI strength. With rate expectations shifting and valuations stretched, even a 3% move could signal a bigger trend. Is momentum building, or fading?

Current Price	$3.65
Prev Close	$3.75
Open	$3.74
Dividend Yield	0.00%
50-Day Moving Average	$4.91
Beta	1.27
Avg. Volume	6.61M
PE Ratio	-5.33

52-Week High	$7.55
52-Week Low	$2.12
Market Capitalization	$457.51M
EPS (Annual)	-$0.5089
Price to Book	-111.05
Revenue Per Employee	$405,359.16

AQST
Aquestive Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AQST News

AQSTAquestive Therapeutics Inc